Publications by authors named "Laura Nicolais"
Unlabelled: The rarity and lack of Level I Evidence compromise our ability to care for patients with gallbladder cancer.
Methods: NCDB cohort study of with resected Stage Groups IB-IVA gallbladder adenocarcinoma between 2004 and 2018. Patients were included.
Textbook outcome as a composite measure of quality in hepaticopancreatic surgery.
J Hepatobiliary Pancreat Sci
October 2023
Background: Textbook outcome (TO) is a valuable metric to assess postoperative outcomes. The aim of this study was to assess TO in patients undergoing hepatopancreatic surgery.
Methods: This was a retrospective cohort NSQIP study from 2015 to 2018.
Introduction: Minimally invasive (MI) surgery has been widely adopted to treat left-sided pancreatic cancer. However, outcomes are not clearly defined.
Materials: Retrospective cohort study utilizing NCDB and NSQIP data.
Background: Seminal trials have demonstrated improved survival in pancreatic adenocarcinoma with novel multiagent chemotherapy regimens. To understand the clinical ramifications of this paradigm shift, we reviewed our institutional experience.
Methods: This retrospective cohort study utilized a prospective database at a single institution to study all patients diagnosed with and treated for pancreatic adenocarcinoma between 2000 and 2020.
Objectives: The advent of effective chemotherapy regimens has increased the use of neoadjuvant multiagent chemotherapy in pancreatic cancer. However, the effect of tumor downstaging with neoadjuvant treatment on survival is unclear.
Methods: Retrospective study included all resected patients with pancreatic adenocarcinoma who underwent neoadjuvant chemotherapy with FOLFIRINOX or gemcitabine/Abraxane.
Article Synopsis
- Downstaging, which is linked to better survival in various cancers, shows mixed results for patients with pancreatic cancer undergoing neoadjuvant therapies.
- A study analyzed nearly 74,000 pancreatic cancer patients and found that while neoadjuvant multiagent chemotherapy (N-MAC) improved post-surgery survival rates, neoadjuvant radiation therapy (N-RT) did not provide a similar survival advantage despite having similar downstaging rates.
- The research highlights that the growing use of N-MAC offers significant benefits for survival in pancreatic cancer patients, contrasting with N-RT, where downstaging does not correlate with improved outcomes.
Introduction: Over the last decade, a paradigm shift has been made in treating pancreatic cancer. Starting in 2011, several trials demonstrated a survival advantage for multiagent chemotherapy (MAC). However, the implication for survival at the population level remains unclear.
View Article and Find Full Text PDFMethods: This study is a retrospective cohort study of National Cancer Data Base (NCDB) data for pancreatic cancer with vascular involvement.
Results: A total of 23 903 patients with vascular involvement were included and divided into 3 groups; no treatment (40.6%), medical treatment (36.
Background: Loss of independence (LOI) is a significant concern for patients undergoing high-risk abdominal surgery. Although the risk for morbidity and mortality has been well studied, there is a dearth of data on risk for LOI.
Methods: This study utilized NSQIP data from 2015 to 2018 in a retrospective cohort study of patients undergoing high-risk gastrointestinal surgery (e.
Objectives: Surgeons have created numerous iterations of the pancreatic fistula risk score (FRS) to predict risk for clinically relevant postoperative pancreatic fistula (CR-POPF). The multitude of often conflicting models makes it difficult for surgeons to apply data in clinical practice.
Methods: We conducted a retrospective cohort study utilizing National Surgical Quality Improvement Program data from 2015 to 2018.